Topical cyclosporin A in the treatment of anterior segment inflammatory disease

E. J. Holland, T. W. Olsen, J. M. Ketcham, C. Florine, J. H. Krachmer, J. J. Purcell, S. Lam, H. H. Tessler, J. Sugar

Research output: Contribution to journalArticlepeer-review

124 Scopus citations


Topical cyclosporin A was used in the management of 43 patients with a variety of anterior segment inflammatory disorders that had failed corticosteroid treatment. Treatment with topical cyclosporin A ranged from 1 week to 43 months, with a mean treatment period of 13 months. Thirty-five patients (81%) with disorders including high-risk keratoplasty, atopic and vernal keratoconjunctivitis, ligneous conjunctivitis, ulcerative keratitis, and Mooren's ulcer had a beneficial result, with resolution, reduction, or prevention of inflammation. Six patients (14%) with scleritis, ocular cicatricial pemphigoid, or endotheliitis showed no clinical improvement. Two patients (5%) had significant ocular discomfort, and the drug had to be discontinued in them. None of the other patients developed local side effects. Twenty-seven of these patients were followed with serial cyclosporin A blood levels and serum creatinine. None of these patients developed measurable drug blood levels or renal toxicity.

Original languageEnglish (US)
Pages (from-to)413-419
Number of pages7
Issue number5
StatePublished - 1993

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Topical cyclosporin A in the treatment of anterior segment inflammatory disease'. Together they form a unique fingerprint.

Cite this